🔴 BioXcel Therapeutics is trading 10.1% down in pre-market as Q2 revenue and EPS miss estimates

BioXcel Therapeutics is trading at $1.07, down -10.10% after its August 13, 2026 Q2 earnings release missed expectations.

• EPS was -$0.490 versus -$0.423 estimated; revenue was $182K versus $403.32K expected.
• The company reported a $14.7 million quarterly net loss, while ongoing financial distress and substantial debt add pressure.
• The decline follows three consecutive advancing sessions.